Boston Scientific has announced a significant delay in its acquisition of Penumbra, pushing the closing date to Q1 2027 due to regulatory hurdles. This delay, coupled with increased financing costs from higher interest rates, is expected to create an earnings drag and diminish the overall benefits of the deal, impacting investor sentiment for both companies.
Boston Scientific's announcement of a substantial delay in its $14.5 billion acquisition of Penumbra, now expected to close in Q1 2027, is a significant development. The delay is attributed to regulatory processes, which introduces uncertainty and extends the period of integration. Furthermore, the company explicitly stated that higher interest rates have increased financing costs, leading to an 'earnings drag' and a reduction in the 'overall benefits of the acquisition.' This news is negative for both BSX, which faces increased costs and a prolonged wait for strategic benefits, and PEN, which will experience a longer period of uncertainty regarding its future. In the short term, this could lead to downward pressure on both stocks as investors re-evaluate the deal's value and timeline. Long-term, the reduced benefits could impact BSX's growth projections and profitability.